On 28 de out. de 2025, ALKS reported earnings of 0.49 USD per share (EPS) for Q3 25, beating the estimate of 0.30 USD, resulting in a 59.82% surprise. Revenue reached 394.19 milhão, compared to an expected 363.27 milhão, with a 8.51% difference. The market reacted with a +4.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of 0.34 USD, with revenue projected to reach 386.14 milhão USD, implying an diminuir of -30.61% EPS, and diminuir of -2.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Alkermes Inc. plc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alkermes Inc. plc reported EPS of $0.49, beating estimates by 59.82%, and revenue of $394.19M, 8.51% above expectations.
How did the market react to Alkermes Inc. plc's Q3 2025 earnings?
The stock price moved up 4.31%, changed from $29.72 before the earnings release to $31.00 the day after.
When is Alkermes Inc. plc expected to report next?
The next earning report is scheduled for 10 de fev. de 2026.
What are the forecasts for Alkermes Inc. plc's next earnings report?
Based on 18
analistas, Alkermes Inc. plc is expected to report EPS of $0.34 and revenue of $386.14M for Q4 2025.